Home > Insider Trading > Filing (0001735276-24-000018)

Filing Details

Accession Number:: 0001735276-24-000018
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-29 16:18:02
Reporting Period:: 2024-02-27

Accepted Time:: 2024-02-29 16:18:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1446125	Yvonne Greenstreet	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-27	5,921	$0.00	51,060	No	4	M	Direct
Common Stock	Disposition	2024-02-28	1,259	$154.54	49,801	No	4	S	Direct
Common Stock	Disposition	2024-02-28	993	$155.45	48,808	No	4	S	Direct
Common Stock	Disposition	2024-02-28	588	$156.38	48,220	No	4	S	Direct
Common Stock	Disposition	2024-02-28	84	$157.30	48,136	No	4	S	Direct
Common Stock	Disposition	2024-02-28	8	$158.09	48,128	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-02-27	5,921	$0.00	5,921	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,842			No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	407	Indirect	by Managed Account

Footnotes

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.